Facial myokymia in multiple system atrophy
β Scribed by Dr. S. B. Blunt; N. M. Khalil; G. D. Perkin
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 400 KB
- Volume
- 12
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Two patients are described with clinical and neuroimaging features consistent with a diagnosis of multiple system atrophy (MSA). The patients are unusual in that facial myokymia became apparent clinically at some stage in their illness. In each patient, the nature and severity of the involuntary facial movements evolved over the course of the illness. Electrophysiologically the movement pattern was consistent with myokymia, and studies of blinkβreflex responses suggested that the myokymic discharges were of brainstem origin. Involuntary facial movements described as facial action myoclonus with electrical characteristics consistent with myoclonus have been described previously in hereditary olivopontocerebellar atrophy (OPCA). Our report describes electrical and clinical features of facial myokymia in MSA with electrical features suggesting hyperexcitability of the facial motorneurons in the brainstem. Such myokymic movements may occur more frequently in MSA than previously recognised but may be missed clinically because of their evolving nature.
π SIMILAR VOLUMES
## Abstract We here report survival in patients with multiple system atrophy (MSA) in a large, prospectively studied group of patients with MSA. Eightyβfive of 100 patients were known to have died. Three patients were rediagnosed as having PD. Twentyβfour patients came to autopsy, which showed MSA
This review provides an update on therapeutic principles and their implications for practical management in multiple system atrophy (MSA), a sporadic neurodegenerative disorder characterized clinically by various combinations of dysautonomia, Parkinsonism, or cerebellar ataxia, often associated with
Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder that usually manifests in the early sixth decade of life and progresses relentlessly with a mean survival of 9 years. Clinically, MSA is dominated by autonomic/urogenital failure, which may be associated with either levodopa (L-d
Lynch and Sima [I] point out that glial cytoplasmic inclusions (GCIs
Patients with multiple system atrophy (MSA) have a mean survival of 8 to 10 years. Nocturnal stridor has been considered a poor prognostic feature. We analyzed demographic, clinical, and polysomnographic data and obtained follow-up information from 42 patients with MSA (30 with follow-up data) seen